Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

Also called NCT01520285

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 281 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01520285
Other papers using this trial's data
  • Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability Current medical research and opinion, 2016-10 DOI, PubMed 27779454

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01520285. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
Acronym
Zanidip
Condition
Hypertension
Intervention (Drug)
Zanidip
Intervention (Drug)
Felodipine sustained-release tablet
Lead sponsor
Lee's Pharmaceutical Limited (class: industry)

Record details

Record id
cardio:ct-nct01520285
Content hash
f76387d1492877f842c01b38dfb25c578807fd05ce8209a3dc53ae5d9da0beb5